TS 091

Drug Profile

TS 091

Alternative Names: TS 0911; TS-091

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Sleep disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Narcolepsy
  • Phase I Hypersomnia

Most Recent Events

  • 28 Jul 2016 Taisho Pharmaceutical completes a phase II trial in Narcolepsy in Japan before July 2016 (JapicCTI142529)
  • 30 Jan 2015 Phase-I clinical trials in Hypersomnia in Japan (PO)
  • 21 Apr 2014 Phase-II clinical trials in Narcolepsy in Japan (PO) (JapicCTI142529)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top